GEHC · GE HealthCare Technologies Inc. — Medical Imaging Duopoly at Discount

Research Date: May 12, 2026 Market Cap: ~$28.9B Research Type: Phase 2 Formal — Fact-based draft with cross-verified public sources

Data Credibility & Verification Layer

This report is based on the following data sources:

Limitations:

• No local fact sheets (EDGAR machine-readable financials not onboarded)
• GEHC was spun off from GE in January 2023; independent history is only ~3.5 years
• Pre-/post-spinoff data comparability is limited
• Company is undergoing major organizational restructuring (merging Imaging + AVS into AIS)
• No FactSet / Bloomberg consensus estimates

Key Takeaways

Thesis: GEHC is one of two global duopoly leaders in medical imaging equipment (alongside Siemens Healthineers). Since spinning off from GE, the company focuses on medical imaging (CT/MR/ultrasound), pharmaceutical diagnostics (contrast agents), and patient monitoring. It has a massive installed base (4M+ devices globally) and high-margin service/consumables revenue streams. However, Q1 2026 brought headwinds from tariff impacts (-$90M operating income) and a PDx recall (-$0.05 EPS), leading to a full-year profit guidance cut. The stock pulled back -13% to near its 52-week low, creating a potential contrarian entry point.

Scenario Analysis (educational illustration only):

• Bear: $52 (PE 11x -- full tariff impact + sustained margin deterioration)
• Base: $72 (PE 15x -- guidance delivered + tariff relief)
• Bull: $88 (PE 18x -- AI imaging platformization + organic growth acceleration)

Key Risks:

1. Tariff impact (Q1 reduced OI by ~$90M; full-year impact could be larger)
2. Margin compression (FY2026 adj EBIT margin cut from 16%+ to 15.4-15.7%)
3. PDx recall (supplier-related recall cost Q1 EPS -$0.05)
4. Post-spinoff transition (organizational restructuring may create short-term execution risk)

Note: No position recommendations. See Disclaimer.

1. Business Overview

Business Segments (2026 Structure)

GEHC reorganized in 2026, merging the former Imaging and Advanced Visualization Solutions (AVS) divisions into Advanced Imaging Solutions (AIS):

Core Product Lines

Competitive Advantages

1. Installed base: 4M+ devices globally -- service, parts, and upgrade revenue is highly recurring
2. Brand recognition: The "GE" brand has 50+ years of history in medical imaging
3. Global coverage: Direct service network in 160+ countries
4. AI imaging: Edison AI platform with 140+ FDA-cleared AI applications

2. Financial Deep Dive

Recent Quarterly Trend

Key observations:

1. Revenue grew +7.4% (reported) / +2.9% (organic): Gap due to FX and consolidation effects
2. Adj EBIT margin contracted sharply: 13.5% vs. Q4 2025's 17.0% (-350bp), driven by:
   • Tariff impact of ~$90M on operating income
   • PDx supplier-related recall costing -$0.05 EPS
   • Seasonality (Q1 is typically the weakest quarter)
3. Operating income declined: $515M vs. Q1 2025's $629M (-18%)
4. PDx stood out positively: +9.7% organic growth, confirming strong contrast agent demand
5. PCS dragged: -8.1% organic, EBIT margin just 1.4% (-500bp YoY)

FY2026 Guidance Revision

Balance Sheet

Balance sheet notes:

• Goodwill of $14B is a result of spinoff accounting treatment, not accumulated acquisitions. Impairment risk is low
• Net debt of $9B was inherited from GE. Management is committed to repaying $1-1.5B annually
• Leverage at 2.8x is elevated for a medical device company, but stable cash flows can support it
• Deleveraging path: Net Debt/EBITDA declining from 2.8x toward 2.0x over 2-3 years

3. Growth Drivers & Catalysts

Catalyst 1: Valuation at all-time lows (contrarian opportunity) Forward PE of 12.9x is the lowest since GEHC's IPO. The stock trades at $63 vs. a 52-week high of $90 (-30%). Tariffs and the PDx recall are one-time or recoverable events. If margins recover to 16%, PE 15x implies ~$73 (+15% upside).

Catalyst 2: PDx high growth + high margins Q1 2026 PDx grew +9.7% organically (fastest segment). Contrast agent and radiopharmaceutical demand correlates directly with imaging exam volumes. PET-CT penetration is driving radiopharmaceutical demand higher. PDx alone could be worth >$10B in a sum-of-the-parts valuation.

Catalyst 3: AI imaging commercialization Edison AI platform has 140+ FDA-cleared applications. AI-assisted diagnostics can increase per-device ARPU. Rising software/SaaS revenue share would structurally improve margins and could drive PS multiple expansion.

Catalyst 4: Potential tariff exemptions Medical devices qualify as "critical infrastructure." Historically, medical products have received tariff exemptions. If US-China tariff tensions ease, the $90M/quarter OI hit would reverse, adding ~$0.30-0.40 to annual EPS.

Catalyst 5: Deleveraging improves equity value Management targets $1-1.5B in annual debt repayment. Net Debt/EBITDA declining from 2.8x to 2.0x over 2-3 years. Every $1B of debt reduction saves approximately $0.07 in EPS through lower interest expense.

4. Risk Analysis

Risk 1: Tariff impact could persist long-term Q1 2026 tariffs reduced OI by $90M and CFO by $110M. If tariffs are not relieved, the full-year impact could exceed $360M in operating income. GEHC has a globally diversified supply chain with meaningful China manufacturing exposure. Monitor: US-China trade policy and medical device tariff exemption decisions.

Risk 2: PCS segment sustained weakness Q1 2026 PCS organic revenue fell -8.1%, with EBIT margin at just 1.4% (-500bp YoY). The patient monitoring equipment cycle is in a downturn. Trigger: PCS posting EBIT losses for two consecutive quarters.

Risk 3: Margin recovery falls short FY2026 adj EBIT margin guidance of 15.4-15.7% is well below FY2025's ~16.5%. Tariffs, inflation, and reorganization costs may persist. Trigger: margin dropping below 14%.

Risk 4: China volume-based procurement (VBP) China is GEHC's second-largest market (~15% of revenue). Medical device procurement reforms continue expanding to more categories, potentially forcing 10-30% price cuts on high-end imaging equipment. Trigger: CT/MR added to national-level procurement auctions.

Risk 5: Post-spinoff operational transition Operating independently from GE requires building standalone IT, finance, and HR infrastructure. Transition costs may continue for 2-3 years. The 2026 organizational restructuring (AIS merger) adds execution risk. Monitor: SG&A trends and management turnover.

5. Valuation Framework

Current Valuation

Shares Outstanding: ~457M
Current Price: $63.29
Market Cap: ~$28.9B
TTM Revenue: ~$20.6B
TTM Adj EPS: ~$5.53 (FY2025 basis)
Net Debt: ~$9.0B
EV: ~$37.9B

PE (TTM, Adj): ~11.4x (using FY2025 EPS $5.53)
PE (FWD, FY2026 midpoint $4.90): ~12.9x
PS (TTM): ~1.4x
EV/EBITDA: ~10-11x
EV/Revenue: ~1.84x
FCF Yield: ~5.5% (FY2026 FCF guidance $1.6B)

Historical Valuation Comparison

Valuation Methods (educational illustration only)

FCF Yield of 5.5% vs. 10Y Treasury 4.4% provides 110bp of risk premium -- healthier than most tech stocks. Forward PE of 12.9x is at its all-time low, fully reflecting tariff headwinds, margin compression, and the PDx recall.

Peer Comparison

GEHC is the "discount option" within the medical imaging duopoly. Its PE of ~15x is 46% below Siemens Healthineers' 28x, reflecting market concerns about standalone post-spinoff operations and tariff exposure. If margins recover to 16%+, the valuation gap has meaningful room to narrow.

Tracking Metrics

This report is for educational purposes only and does not constitute investment advice. All data sourced from SEC EDGAR filings and public company disclosures. See full Disclaimer.